<qa>  What is the maximum dose of ABT-888?I. To determine the maximum-tolerated dose MTD of ABT-888 veliparib in combination with bendamustine bendamustine hydrochloride in patients with solid tumors, lymphoma, or multiple myeloma. Phase Ib II. To establish the safety of ABT-888 in combination with bendamustine and rituximab in an expansion cohort of patients with non-Hodgkin lymphoma NHL. Phase Ib III. To assess the toxicity profile of this regimen in the above patients. Phase Ib IV. To determine the complete response CR rate in patients with indolent NHL or mantle cell lymphoma MCL treated with ABT-888 bendamustine rituximab. Phase IIa 